Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Acq. announced
Consulting agrmnt
Enliven Therapeutics, Inc. (IMRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Enliven Therapeutics, Inc. Selected Condensed Consolidated Financial Information Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 15,183 $ 7,937 $ 27,063 $ 14,996 General and administrative 4,951 1,079 9,489 2,698 Total operating expenses 20,134 9,016 36,552 17,694 Loss from operations Other income , net 3,413 127 5,107 136 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average shares outstanding, basic and diluted 40,961 3,104 29,862 2,991 Balance Sheets June 30, December 31, 2023 2022 Assets Current assets: Cash, cash equivalents and marketable securities $ 277,865 $ 75,536 Prepaid expenses and other current assets 5,310 2,217 Total current assets 283,175 77,753 Pr..."
05/11/2023 8-K Quarterly results
Docs: "Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results"
11/09/2021 8-K Quarterly results
Docs: "Imara Reports Third Quarter 2021 Financial Results and Business Highlights Interim analysis data for Phase 2b clinical trials of tovinontrine in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021"
08/06/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
03/05/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Patient Dosing Underway in Phase 2b Clinical Trials: Imara dosed the first patients in both its Ardent Phase 2b sickle cell disease clinical trial and its Forte Phase 2b beta-thalassemia clinical trial. Imara plans to report formal interim analyses from the Ardent and Forte Phase 2b clinical trials when 33 and 30 patients, respectively, have completed 24 weeks of treatment. Due to COVID-19 related recruitment delays, the company expects to report interim data from the Ardent and Forte Phase 2b clinical trials in the second half of 2021 rather than the first half of 2021 as originally planned. • Completed Dosing in Phase 2a Clinical Trial: Imara completed dosing patients in the Phase 2a clinical trial in patients with SCD during the third quarter of 2020 and plans to report top-line ..."
08/14/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "Closed IPO: In March 2020, Imara closed its initial public offering with gross proceeds of $75.2 million. The Company’s common stock began trading on the Nasdaq Global Select Market under the symbol IMRA on March 12, 2020. In April, the underwriters exercised their option to purchase an additional 705,000 shares of common stock, resulting in additional gross proceeds of $11.3 million. • Progressed Clinical Trials: The Company continues to make progress toward initiating its Phase 2b studies in sickle cell disease and beta-thalassemia. It anticipates screening to begin for both programs in the U.S. in the coming weeks with a continued goal of dosing the first patients by the end of the second quarter of 2020. While the ongoing COVID-19 pandemic may cause delays in initiation, Imara i..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy